132 related articles for article (PubMed ID: 8549033)
1. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine.
Stein CM; Kinirons MT; Pincus T; Wilkinson GR; Wood AJ
Clin Pharmacol Ther; 1996 Jan; 59(1):47-51. PubMed ID: 8549033
[TBL] [Abstract][Full Text] [Related]
2. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients.
Schmidt LE; Olsen AK; Stentoft K; Rasmussen A; Kirkegaard P; Dalhoff K
Clin Pharmacol Ther; 2001 Nov; 70(5):446-54. PubMed ID: 11719731
[TBL] [Abstract][Full Text] [Related]
3. Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients.
Schmidt LE; Rasmussen A; Kirkegaard P; Dalhoff K
Transplantation; 2003 Jul; 76(2):358-63. PubMed ID: 12883193
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test.
Krivoruk Y; Kinirons MT; Wood AJ; Wood M
Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 1):608-14. PubMed ID: 7995002
[TBL] [Abstract][Full Text] [Related]
5. Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe.
Villeneuve JP; L'Ecuyer L; De Maeght S; Bannon P
Clin Pharmacol Ther; 2000 Mar; 67(3):242-8. PubMed ID: 10741627
[TBL] [Abstract][Full Text] [Related]
6. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients.
Cakaloglu Y; Tredger JM; Devlin J; Williams R
Hepatology; 1994 Aug; 20(2):309-16. PubMed ID: 7519161
[TBL] [Abstract][Full Text] [Related]
7. Prediction of interpatient and intrapatient variation in OG 37-325 dosing requirements by the erythromycin breath test. A prospective study in renal transplant recipients.
Turgeon DK; Leichtman AB; Blake DS; Schmouder RL; Lown KS; Annesley TM; Watkins PB
Transplantation; 1994 Jun; 57(12):1736-41. PubMed ID: 8016878
[TBL] [Abstract][Full Text] [Related]
8. Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization.
Chiou WL; Jeong HY; Wu TC; Ma C
Clin Pharmacol Ther; 2001 Oct; 70(4):305-10. PubMed ID: 11673745
[No Abstract] [Full Text] [Related]
9. Erythromycin breath test and clinical transplantation.
Watkins PB
Ther Drug Monit; 1996 Aug; 18(4):368-71. PubMed ID: 8857552
[TBL] [Abstract][Full Text] [Related]
10. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity.
Kurnik D; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 2006 Sep; 80(3):228-34. PubMed ID: 16952489
[TBL] [Abstract][Full Text] [Related]
11. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men.
Kinirons MT; O'Shea D; Downing TE; Fitzwilliam AT; Joellenbeck L; Groopman JD; Wilkinson GR; Wood AJ
Clin Pharmacol Ther; 1993 Dec; 54(6):621-9. PubMed ID: 8275617
[TBL] [Abstract][Full Text] [Related]
12. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
Wandel C; Lang CC; Cowart DC; Girard AF; Bramer S; Flockhart DA; Wood AJ
Clin Pharmacol Ther; 1998 May; 63(5):506-11. PubMed ID: 9630823
[TBL] [Abstract][Full Text] [Related]
13. Metabolic interactions of putative cytochrome P4503A substrates with alternative pathways of dapsone metabolism in human liver microsomes.
Irshaid Y; Branch RA; Adedoyin A
Drug Metab Dispos; 1996 Feb; 24(2):164-171. PubMed ID: 8742227
[TBL] [Abstract][Full Text] [Related]
14. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
Masica AL; Mayo G; Wilkinson GR
Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
[TBL] [Abstract][Full Text] [Related]
15. Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors.
Bluhm RE; Adedoyin A; McCarver DG; Branch RA
Clin Pharmacol Ther; 1999 Jun; 65(6):598-605. PubMed ID: 10391665
[TBL] [Abstract][Full Text] [Related]
16. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.
Kinirons MT; O'Shea D; Kim RB; Groopman JD; Thummel KE; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 1999 Sep; 66(3):224-31. PubMed ID: 10511057
[TBL] [Abstract][Full Text] [Related]
17. Erythromycin breath test.
Rivory LP; Watkins PB
Clin Pharmacol Ther; 2001 Oct; 70(4):395-9. PubMed ID: 11673756
[No Abstract] [Full Text] [Related]
18. Optimizing the erythromycin breath test for use in cancer patients.
Rivory LP; Slaviero K; Seale JP; Hoskins JM; Boyer M; Beale PJ; Millward MJ; Bishop JF; Clarke SJ
Clin Cancer Res; 2000 Sep; 6(9):3480-5. PubMed ID: 10999732
[TBL] [Abstract][Full Text] [Related]
19. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test.
Cheng CL; Smith DE; Carver PL; Cox SR; Watkins PB; Blake DS; Kauffman CA; Meyer KM; Amidon GL; Stetson PL
Clin Pharmacol Ther; 1997 May; 61(5):531-43. PubMed ID: 9164415
[TBL] [Abstract][Full Text] [Related]
20. Erythromycin breath test.
Watkins PB
Clin Pharmacol Ther; 2000 May; 67(5):577-8. PubMed ID: 10824637
[No Abstract] [Full Text] [Related]
[Next] [New Search]
